{
    "clinical_study": {
        "@rank": "16716", 
        "arm_group": [
            {
                "arm_group_label": "9 mW/cm2", 
                "arm_group_type": "Active Comparator", 
                "description": "CCL-VARIO UV lamp Riboflavin 0.1% ophthalmic solution"
            }, 
            {
                "arm_group_label": "18 mW/cm2", 
                "arm_group_type": "Active Comparator", 
                "description": "CCL-VARIO at 18 mW/cm2 Riboflavin 0.1% ophthalmic solution"
            }
        ], 
        "brief_summary": {
            "textblock": "The primary objective of this study is to determine the effectiveness and safety of corneal\n      collagen cross-linking at irradiance levels of 9 and 18 mW/cm2."
        }, 
        "brief_title": "Study of the Safety and Effectiveness of Collagen Cross-Linking at an Irradiance of 9 mW/cm2 and 18 mW/cm2", 
        "condition": [
            "Keratoconus", 
            "Corneal Ectasia"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Dilatation, Pathologic", 
                "Keratoconus", 
                "Corneal Diseases"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "General Inclusion Criteria\n\n        Prospective subjects must meet all of the following criteria to be eligible for\n        participation:\n\n          -  18 years of age or older\n\n          -  Signed written informed consent\n\n          -  Willingness and ability to comply with schedule for follow-up visits\n\n          -  Contact lens removal prior to evaluation and treatment\n\n        Inclusion criteria for progressive keratoconus\n\n        Prospective subjects must meet two of the following criteria:\n\n          -  Having a diagnosis of progressive keratoconus:\n\n          -  An increase of \u2265 1.00 D in the steepest keratometry value\n\n          -  An increase of  \u2265 1.00 D in astigmatism manifest refraction\n\n          -  A myopic shift (decrease in the spherical equivalent) of \u2265 0.50 D on subjective\n             manifest refraction\n\n          -  Presence of central or inferior steepening on the Pentacam map.\n\n          -  Axial topography consistent with keratoconus\n\n          -  Steepest keratometry (Kmax) value \u2265 47.00 D\n\n        Inclusion criteria for ectasia\n\n        Prospective subjects must meet the following criteria:\n\n          -  History of having undergone a keratorefractive procedure\n\n          -  Meeting two of the following criteria\n\n          -  Steepening by topography, either Pentacam or Humphrey\n\n          -  Thinning of cornea\n\n          -  Shift in the position of thinnest portion of cornea\n\n          -  Change in refraction with increasing myopia\n\n          -  Development of myopic astigmatism\n\n          -  Development of irregular astigmatism\n\n          -  Loss of best spectacle corrected acuity. 6.2 Exclusion Criteria\n\n        Subjects meeting any of the following criteria will be excluded from this protocol:\n\n          -  Eyes classified as either normal, atypical normal,\n\n          -  Corneal pachymetry \u2264 350 microns at the thinnest point measured by Pentacam in the\n             eye to be treated\n\n          -  A history of chemical injury or delayed epithelial healing in the eye to be treated.\n\n          -  Pregnancy (including plan to become pregnant) or lactation during the course of the\n             study\n\n          -  A known sensitivity to study medications\n\n          -  Patients with nystagmus or any other condition that would prevent a steady gaze\n             during the treatment\n\n          -  Inability to cooperate with diagnostic tests.\n\n          -  Patients with a current condition that, in the investigator's opinion, would\n             interfere with or prolong epithelial healing.\n\n          -  Taking Vitamin C (ascorbic acid) supplements within 1 week of the cross-linking\n             treatment.\n\n          -  Patients who are unable to remain supine and tolerate a lid speculum for an\n             extended period of time."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 9, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02009709", 
            "org_study_id": "MEC-0001"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "9 mW/cm2", 
                    "18 mW/cm2"
                ], 
                "description": "Instillation of 0.1% riboflavin ophthalmic solution, one drop every 3 minutes for 30 minutes before the procedure and one drop every 3 minutes during the procedure.", 
                "intervention_name": "Riboflavin 0.1% ophthalmic solution", 
                "intervention_type": "Drug", 
                "other_name": [
                    "CXL", 
                    "CCL", 
                    "crosslinking"
                ]
            }, 
            {
                "arm_group_label": "9 mW/cm2", 
                "description": "Application of ultraviolet light on the eye to be treated at an irradiance of 9 mW/cm2 for 10 minutes", 
                "intervention_name": "CCL-VARIO UV lamp", 
                "intervention_type": "Device", 
                "other_name": [
                    "CXL", 
                    "CCL", 
                    "crosslinking"
                ]
            }, 
            {
                "arm_group_label": "18 mW/cm2", 
                "description": "Application of ultraviolet light on the eye to be treated at an irradiance of 18 mW/cm2 for 5 minutes.", 
                "intervention_name": "CCL-VARIO at 18 mW/cm2", 
                "intervention_type": "Device", 
                "other_name": [
                    "CXL", 
                    "CCL", 
                    "crosslinking"
                ]
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Riboflavin"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "keratoconus", 
            "collagen crosslinking", 
            "crosslinking", 
            "ectasia"
        ], 
        "lastchanged_date": "April 30, 2014", 
        "location": {
            "contact": {
                "email": "adamb@occhicago.com", 
                "last_name": "Adam Baruch", 
                "phone": "847-755-9393"
            }, 
            "facility": {
                "address": {
                    "city": "Hoffman Estates", 
                    "country": "United States", 
                    "state": "Illinois", 
                    "zip": "60169"
                }, 
                "name": "Mack Eye Center"
            }, 
            "investigator": [
                {
                    "last_name": "Robert J Mack, M.D.", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Monica Denny, OD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Puja Shah, OD", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Study of the Safety and Effectiveness of Photochemically Induced Collagen Cross-Linking at an Irradiance of 9 mW/cm2 and 18 mW/cm2 in Eyes With Keratoconus or Ectasia", 
        "overall_contact": {
            "email": "rjsmack@aol.com", 
            "last_name": "Robert J Mack, M.D.", 
            "phone": "847-755-9393"
        }, 
        "overall_official": {
            "affiliation": "Mack Eye Center", 
            "last_name": "Robert J Mack, M.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "January 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Decrease in maximum corneal curvature", 
            "safety_issue": "Yes", 
            "time_frame": "3 and 6 months post-procedure"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02009709"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Mack Eye Center", 
            "investigator_full_name": "Robert Mack, M.D.", 
            "investigator_title": "Sponsor-Investigator", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "source": "Mack Eye Center", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Robert Mack, M.D.", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}